Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 12/20 | 0.43 |
| ▸ | ESRRA | P11474 | 1/20 | 0.42 |
| ▸ | PNLIP | P16233 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2888429 | 0.88 | ESRRA (0.46) | P2RY1ESRRAPNLIPTDP1CYP1A2 | |
| SCHEMBL12952688 | 0.82 | P2RY1 (0.58) | P2RY1TDP1P2RY14 | |
| SCHEMBL2884687 | 0.80 | L3MBTL1 (0.44) | ESRRAPNLIPTDP1CYP1A2CYP3A4 | |
| SCHEMBL2892865 | 0.78 | ESRRA (0.46) | ESRRACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2892667 | 0.75 | GAA (0.47) | ESRRAPNLIPTDP1NPSR1 | |
| SCHEMBL2890797 | 0.74 | PNLIP (0.45) | P2RY1PNLIPCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2884655 | 0.73 | SLC6A2 (0.48) | P2RY1P2RY14P2RY2CYP3A4 | |
| SCHEMBL2893274 | 0.72 | PTGDR2 (0.47) | ESRRAPNLIPTDP1 | |
| SCHEMBL2885405 | 0.71 | L3MBTL1 (0.45) | PNLIPTDP1ATMNPSR1 | |
| SCHEMBL16316797 | 0.71 | L3MBTL1 (0.56) | ESRRATDP1ATMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8558028-B2 | Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase | UNIVERSITY OF BATH OF CLAVERTON DOWN (GB) | 2013-10-15 | — | — | US | disclosed |
| US-20100286204-A1 | COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2220026-A2 | INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGENASE | Sterix Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009066072-A2 | COMPOUND | STERIX LIMITED (GB) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286204-A1 | COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE | HSD17B13, HSD17B3, HSD3B2 | P2RY1 4597/4885ESRRA 79/4885PNLIP 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.